Safety, Pharmacokinetics, and Pharmacodynamics of a Single, Ascending Dose of WAL0921 in Healthy Subjects
Latest Information Update: 17 Apr 2024
Price :
$35 *
At a glance
- Drugs WAL 0921 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; First in man
- Sponsors Walden Biosciences
- 15 Apr 2024 Positive top-line data presented in a Walden Biosciences Media Release.
- 08 Apr 2024 Status changed from recruiting to completed.
- 10 Jan 2024 According to an Walden Biosciences media release, company today announced that it has broadened its research collaboration with the University of Michigan at Ann Arbor (U-M).A key element of the expansion of the collaboration is the inclusion of biomarker analysis of plasma samples from Walden's Phase 1+ clinical study of WAL0921.